Recent Company News

• 09:59 PM ET Jan 29, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 06:51 PM ET Feb 08, 2026
  

  CSPC Pharmaceutical Group initiated buy at Northeast Securities (6-Feb, timing uncertain) (HK$9.66, 0.00)

• 06:46 AM ET Feb 02, 2026
  

  CSPC Pharmaceutical Group obtains NMPA drug registration approval for Clevidipine Injectable Emulsion (HK$9.15, 0.00)

• 02:10 AM ET Jan 30, 2026
  

  AstraZeneca to pay $1.2B upfront in multi-billion-dollar CSPC Pharmaceuticals obesity collaboration (13460.0000p, 0)

• 10:59 PM ET Jan 29, 2026
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 07:04 PM ET Jan 29, 2026
  

  CSPC Pharmaceutical enters into strategic collaboration and license agreement with AstraZeneca regarding long-acting peptide medicines (HK$10.69, 0.00)

• 06:50 AM ET Jan 29, 2026
  

  CSPC Pharmaceutical Group obtains NMPA trial approval for SYS6055 injection

• 05:06 AM ET Jan 13, 2026
  

  CSPC Pharmaceutical Group obtains US FDA clinical trial approval for potent aldosterone synthase inhibitor SYH2072 (HK$9.78, 0.00)

• 07:03 AM ET Jan 12, 2026
  

  CSPC Pharmaceutical Group receives NMPA marketing approval for prusogliptin and metformin extended-release tablets (HK$9.46, 0.00)